Lupin launches generic Niaspan tablets in US market

New Delhi, March 22,2014 – Mumbai-based pharma major Lupin Ltd today launched its generic version of Niaspan extended release tablets, used in reducing cholesterol in the US market.

The company’s US subsidiary, Lupin Pharmaceuticals Inc has launched the generic Niaspan tablets in multiple strengths of 500 mg, 750 mg and 1000 mg, having received final approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

These tablets are the generic equivalent of AbbVie Inc’s Niaspan tablets.

Commenting on the launch, Lupin Ltd Managing Director Nilesh Gupta said: “We are happy to launch this product having received approval from the (US) FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market.”

Citing IMS MAT data, the company said Niaspan tablets had annual sales of approximately $1 billion in the US in 2013.

Niaspan tablets are used with one’s diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.

Lupin Ltd shares gained 0.45 per cent on the BSE from the previous close, ending the day at Rs 944.2 per scrip. Business Line